IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages 525-532

  Zhang, Q ^a   Lapalus, M ^a   Asselah, T ^a   Laouenan C ^b   Moucari, R ^a   Martinot Peignoux, M ^a   Bieche, I ^b   Estrabaud, E ^a   De Muynck, S ^a   Boyer, N ^a   Bedossa, P ^c   Vidaud, M ^b   Marcellin, P ^a   Lada, O ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

HBeAg positive; HBsAg seroconversion; hepatitis B virus; IFNL3 polymorphism (rs12979860); response to interferon

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERFERON LAMBDA 3; UNCLASSIFIED DRUG; VIRUS DNA; ALPHA INTERFERON; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HEPATITIS B VIRUS GENOTYPE E; HEPATITIS B VIRUS GENOTYPE G; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BLOOD; CLASSIFICATION; GENETICS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84902257808     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12177     Document Type: Article

References (27)

1. European Association for the Study of the Liver (2012). EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
2. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
3. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Fattovich G, Stroffolini T, Zagni I, et al,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
5. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
6. Marcellin P, Bonino F, Lau GK, et al,. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179 e1-4.
7. Marcellin P, Chang TT, Lim SG, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
8. Lai CL, Shouval D, Lok AS, et al,. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
9. Buster EH, Flink HJ, Cakaloglu Y, et al,. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467.
10. Moucari R, Korevaar A, Lada O, et al,. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
11. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
13. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138 (1338-45): 45 e1-7.
14. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
15. Sonneveld MJ, Wong VW, Woltman AM, et al,. Polymorphisms Near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2011; 142: 513-520.
16. Lampertico P, Vigano M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.
17. Tseng TC, Yu ML, Liu CJ, et al,. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2012; 16: 629-637.
18. Mangia A, Santoro R, Mottola L, et al,. Abst1331-Lack of association between IL28B variants and HBsAg clearance after interferon treatment. J Hepatol 2011; 54: S525.
19. de Niet A, Takkenberg RB, Benayed R, et al,. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol 2012; 47: 475-481.
20. Asselah T, De Muynck S, Broet P, et al,. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 56: 527-532.
21. Li W, Jiang Y, Jin Q, et al,. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31: 1118-1126.
22. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
23. Martin MP, Qi Y, Goedert JJ, et al,. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749-1753.
24. Janssen HL, van Zonneveld M, Senturk H, et al,. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
25. Yalcin K, Degertekin H, Yildiz F, et al,. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36: 1516-1522.
26. Marabita F, Aghemo A, De Nicola S, et al,. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-1134.
27. Bochud PY, Bibert S, Kutalik Z, et al,. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-394.